• Latest
  • Trending
  • All
  • News
  • Business
  • Lifestyle
Novel Antibody May Be Key To Better Lung Cancer Treatment

Novel Antibody May Be Key To Better Lung Cancer Treatment

September 23, 2024
Lee Greenwood on ‘God Bless the USA’ Legacy: ‘That’s Where Patriotism Starts’

Lee Greenwood on ‘God Bless the USA’ Legacy: ‘That’s Where Patriotism Starts’

July 4, 2025
Trump Seeking Military Costumes for Parade

Trump Lambasts Dems Who Voted Against ‘Big, Beautiful Bill’

July 4, 2025
WILL SELLERS: Misunderstanding The Road To Independence

WILL SELLERS: Misunderstanding The Road To Independence

July 4, 2025
Dems’ ‘Project 2029’ May Not Actually Bode Well For Party’s Future

Dems’ ‘Project 2029’ May Not Actually Bode Well For Party’s Future

July 4, 2025
BRILYN HOLLYHAND: Gen Z, It’s Time We Start Acting Like We Deserve The Freedom We Inherited

BRILYN HOLLYHAND: Gen Z, It’s Time We Start Acting Like We Deserve The Freedom We Inherited

July 4, 2025
Dem Eyes House Seat That Swung Nearly 20 Points To Trump

Dem Eyes House Seat That Swung Nearly 20 Points To Trump

July 4, 2025
Outfit Behind Slanted ‘Terrorism’ Studies Pleads For Private Donors After Trump Funding Cuts

Outfit Behind Slanted ‘Terrorism’ Studies Pleads For Private Donors After Trump Funding Cuts

July 4, 2025
Gas Crisis Looms Over California As Dems Continue To Impose Crippling Regs

Gas Crisis Looms Over California As Dems Continue To Impose Crippling Regs

July 4, 2025
Can Elon Musk Shatter America’s Two-Party System?

Can Elon Musk Shatter America’s Two-Party System?

July 4, 2025
‘I’d Be Careful What You Read’: 7 Times Trump Officials Turned Tables On Dem Lawmakers Trying To Corner Them

‘I’d Be Careful What You Read’: 7 Times Trump Officials Turned Tables On Dem Lawmakers Trying To Corner Them

July 4, 2025
Despite Being Subverted By Lower Courts, Trump Scored Big In Latest SCOTUS Term

Despite Being Subverted By Lower Courts, Trump Scored Big In Latest SCOTUS Term

July 4, 2025
How Trump Could Finally Bring Stability To Middle East

How Trump Could Finally Bring Stability To Middle East

July 4, 2025
  • Donald Trump
  • State of the Union
  • Elon Musk
  • Tariffs
  • Congress
  • Faith
  • Immigration
Friday, July 4, 2025
  • Login
IJR
  • Politics
  • US News
  • Commentary
  • World News
  • Faith
  • Latest Polls
No Result
View All Result
IJR
No Result
View All Result
Home FaithTap

Novel Antibody May Be Key To Better Lung Cancer Treatment

by Zenger
September 23, 2024 at 9:41 am
in FaithTap, News, Wire
247 5
0
Novel Antibody May Be Key To Better Lung Cancer Treatment
491
SHARES
1.4k
VIEWS
Share on FacebookShare on Twitter

<p>Photo of lung scan. Novel antibody may be key to better lung cancer treatment. ANNA SHVETS VIA PEXELS.</p> <p>“></p> <p>Lung cancer is the leading cause of cancer-related deaths, and the most common form is a non-small-cell type called adenocarcinoma. </p> <p>The main course of treatment today, a kinase inhibitor drug called Osimertinib, is effective for many adenocarcinoma patients. However, after a year or more, the cancer usually develops resistance to the drug, and the tumor can regrow.</p> <p>Researchers from Israel’s Weizmann Institute of Science reported their success in developing a novel synthetic antibody that, combined with Osimertinib, prevents or slows drug resistance and the relapse of adenocarcinoma tumors in mouse models.</p> <p>The results were published in <em>Cell Reports Medicine.</em></p> <p>“When patients take only the drug, there can be a relapse, and it’s very bad for the patient because the new tumors are more aggressive,” explains lead author Arturo Simoni-Nieves, a postdoc researcher from Mexico who worked on the project in the lab of Prof. Yosef Yarden, his faculty adviser and incumbent of the Harold and Zelda Goldenberg Professorial Chair in Molecular Cell Biology.</p> <p>“The combination of the antibody and the drug targets two different proteins simultaneously in mouse models and helps us avoid the relapsing of the tumors,” Simoni-Nieves says.</p> <p>This phase of the research project took about three years to complete.</p> <p>“Our next task after testing is understanding the mechanism of how it works. Once we get that information, we can think about trying it with human patients,” says Simoni-Nieves. He expects this step to take another two or three years.</p> <p>Future clinical trials would reveal whether this novel antibody can be developed into a new treatment for lung cancer that not only inhibits the disease but also helps prevent its recurrence.</p> <p>“Osimertinib is the only treatment these patients have so far. Maybe with this antibody, we can improve treatment,” says Simoni-Nieves.</p> <p>In addition to Simoni-Nieves and Yarden, the paper has 15 contributing authors, most from the Weizmann Institute, as well as two collaborating researchers from the Graduate School of Pharmaceutical Sciences at Osaka University in Japan and three researchers in Italy, from the Department of Medical and Surgical Sciences of the University of Bologna and from the Università Cattolica del Sacro Cuore in Rome.</p> <p>They concluded that their EGFR-AXL antibody “holds therapeutic promise.”</p> <figure class=

The study was supported by Merck KGaA, the Israel Science Foundation, the European Research Council, the Israel Cancer Research Fund, and the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation.

 

          Produced in association with ISRAEL21c

          Tags: U.S. NewsZenger
          Share196Tweet123
          Zenger

          Zenger

          Advertisements

          Top Stories June 10th
          Top Stories June 7th
          Top Stories June 6th
          Top Stories June 3rd
          Top Stories May 30th
          Top Stories May 29th
          Top Stories May 24th
          Top Stories May 23rd
          Top Stories May 21st
          Top Stories May 17th

          Join Over 6M Subscribers

          We’re organizing an online community to elevate trusted voices on all sides so that you can be fully informed.





          IJR

              Copyright © 2024 IJR

          Trusted Voices On All Sides

          • About Us
          • GDPR Privacy Policy
          • Terms of Service
          • Editorial Standards & Corrections Policy
          • Subscribe to IJR

          Follow Us

          Welcome Back!

          Login to your account below

          Forgotten Password?

          Retrieve your password

          Please enter your username or email address to reset your password.

          Log In
          No Result
          View All Result
          • Politics
          • US News
          • Commentary
          • World News
          • Faith
          • Latest Polls

              Copyright © 2024 IJR

          Top Stories June 10th Top Stories June 7th Top Stories June 6th Top Stories June 3rd Top Stories May 30th Top Stories May 29th Top Stories May 24th Top Stories May 23rd Top Stories May 21st Top Stories May 17th